Success Metrics

Clinical Success Rate
78.6%

Based on 11 completed trials

Completion Rate
79%(11/14)
Active Trials
0(0%)
Results Posted
18%(2 trials)
Terminated
3(20%)

Phase Distribution

Ph phase_2
4
27%
Ph phase_1
11
73%

Phase Distribution

11

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
11(73.3%)
Phase 2Efficacy & side effects
4(26.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

73.3%

11 of 15 finished

Non-Completion Rate

26.7%

4 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(11)
Terminated(4)

Detailed Status

Completed11
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
78.6%
Most Advanced
Phase 2

Trials by Phase

Phase 111 (73.3%)
Phase 24 (26.7%)

Trials by Status

terminated320%
completed1173%
withdrawn17%

Recent Activity

0 active trials
Showing 5 of 15
completedphase_1

Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer

NCT00526461
completedphase_1

Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer

NCT00470496
terminatedphase_2

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

NCT03090412
completedphase_1

Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx

NCT00675233
completedphase_1

A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

NCT01140178
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT00526461Phase 1

Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer

Completed
NCT00470496Phase 1

Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer

Completed
NCT03090412Phase 2

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

Terminated
NCT00675233Phase 1

Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx

Completed
NCT01140178Phase 1

A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

Completed
NCT02119728Phase 2

Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity

Withdrawn
NCT00670397Phase 1

Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer

Terminated
NCT01238042Phase 1

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

Completed
NCT01668823Phase 1

Photodynamic Therapy in Treating Patients With Lung Cancer

Completed
NCT00528775Phase 2

Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages

Terminated
NCT01236443Phase 1

Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus

Completed
NCT00281736Phase 2

Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer

Completed
NCT00060268Phase 1

Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors

Completed
NCT00017485Phase 1

Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer

Completed
NCT00025571Phase 1

Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15